{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:17:13Z","timestamp":1787872633305,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current research in precision oncology focuses on progression-free survival (PFS) and overall survival (OS) as the key outcomes. This stands in stark contrast to the primary outcomes guiding cancer treatment in the clinic- dynamic changes in tumor size in response to treatment. While PFS and OS are meaningful, highly interpretable and easily collected, we hypothesize that revealing associations between somatic mutations and tumor size dynamics can uncover genetic factors that can influence treatment response and generate hypotheses for future clinical investigation, while further improving our understanding of tumor biology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We propose and benchmark a new statistical framework \u2013 Andersen-Gill based Tumor Dynamics (AG-TD) to model recurrent outcomes and apply it to data from ~\u200917\u00a0K radiology reports of patients with non-small cell lung cancer undergoing routine treatment at the Dana-Farber Cancer Institute. Our approach enables modeling recurrent outcomes while considering the time-dependent nature of biomarker-treatment interaction, patient mortality, and loss to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identify 27 somatic mutations that lead to differential response to common treatments including both protective and hazardous effects. Among these, deletions in\n                      <jats:italic>MYBL1<\/jats:italic>\n                      and\n                      <jats:italic>GATA3<\/jats:italic>\n                      were independently validated by replication in an external EGFR-TKI drug sensitivity screen, reaching Bonferroni correction significance. We also identify 13 somatic mutations associated with differential rates of progression and response during the entire treatment course, of which 9 are undetectable using conventional OS or PFS models. We further verify that the results are consistent in a homogeneous sub-cohort of advanced stage (3 and 4) patients only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, we demonstrate the potential for using longitudinal outcomes in cancer genetic studies to complement traditional survival-based analyses, and to enable systematic identification of candidate gene\u2013treatment interactions for future validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01695-x","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:14:13Z","timestamp":1781709253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging tumor dynamics to discover mutations influencing progression and treatment response for precision oncology"],"prefix":"10.1186","volume":"18","author":[{"given":"Ella","family":"Petter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"LoPiccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Groha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Border","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Pasaniuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Kehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Zaitlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature"},{"key":"1695_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138.","journal-title":"Nature"},{"key":"1695_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez F, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20:555\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1695_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1534\/genetics.105.044677","volume":"173","author":"C Greenman","year":"2006","unstructured":"Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer. Genetics. 2006;173:2187\u201398.","journal-title":"Genetics"},{"key":"1695_CR5","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1695_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.aab4082","volume":"349","author":"I Martincorena","year":"2015","unstructured":"Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349:1483\u20139.","journal-title":"Science"},{"key":"1695_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrg3539","volume":"14","author":"IR Watson","year":"2013","unstructured":"Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14:703\u201318.","journal-title":"Nat Rev Genet"},{"key":"1695_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","volume":"17","author":"HH Cheng","year":"2019","unstructured":"Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019;17:515\u201321.","journal-title":"J Natl Compr Canc Netw"},{"key":"1695_CR9","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015;34:3617\u201326.","journal-title":"Oncogene"},{"key":"1695_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI: J Natl Cancer Inst. 2005;97:339\u201346.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"1695_CR11","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci. 2007;104:20932\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"1695_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"S Mok Tony","year":"2017","unstructured":"Mok Tony S, et al. Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"},{"key":"1695_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"1695_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2217\/fon.15.15","volume":"11","author":"N Reguart","year":"2015","unstructured":"Reguart N, Remon J. Common EGFR-mutated subgroups (Del19\/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Future Oncol. 2015;11:1245\u201357.","journal-title":"Future Oncol"},{"key":"1695_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jnci\/djp369","volume":"101","author":"KR Broglio","year":"2009","unstructured":"Broglio KR, Berry DA. Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival. JNCI: J Natl Cancer Inst. 2009;101:1642\u20139.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"1695_CR16","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","volume":"24","author":"SL Mushti","year":"2018","unstructured":"Mushti SL, Mulkey F, Sridhara R. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. Clin Cancer Res. 2018;24:2268\u201375.","journal-title":"Clin Cancer Res"},{"key":"1695_CR17","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50:S122\u201350.","journal-title":"J Nucl Med"},{"key":"1695_CR18","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. JCO. 2015;33:3541\u20133.","journal-title":"JCO"},{"key":"1695_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/d41586-021-03691-0","volume":"600","author":"A Mullard","year":"2021","unstructured":"Mullard A. Half of top cancer studies fail high-profile reproducibility effort. Nature. 2021;600:368\u20139.","journal-title":"Nature"},{"key":"1695_CR20","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1016\/j.csbj.2021.06.040","volume":"19","author":"C Lu","year":"2021","unstructured":"Lu C, Greshake Tzovaras B, Gough J. A survey of direct-to-consumer genotype data, and quality control tool (GenomePrep) for research. Comput Struct Biotechnol J. 2021;19:3747\u201354.","journal-title":"Comput Struct Biotechnol J"},{"key":"1695_CR21","doi-asserted-by":"publisher","first-page":"e04333","DOI":"10.7554\/eLife.04333","volume":"3","author":"TM Errington","year":"2014","unstructured":"Errington TM, et al. An open investigation of the reproducibility of cancer biology research. eLife. 2014;3:e04333.","journal-title":"eLife"},{"key":"1695_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc.2017.32","volume":"17","author":"WG Kaelin","year":"2017","unstructured":"Kaelin WG. Common pitfalls in preclinical cancer target validation. Nat Rev Cancer. 2017;17:441\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1695_CR23","doi-asserted-by":"publisher","first-page":"110569","DOI":"10.1016\/j.celrep.2022.110569","volume":"38","author":"JC Smith","year":"2022","unstructured":"Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers. Cell Rep. 2022;38:110569.","journal-title":"Cell Rep"},{"key":"1695_CR24","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1038\/s41467-021-27358-6","volume":"12","author":"KL Kehl","year":"2021","unstructured":"Kehl KL, et al. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nat Commun. 2021;12:7304.","journal-title":"Nat Commun"},{"key":"1695_CR25","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc B Stat Methodol. 1972;34:187\u2013202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ng.3946","volume":"49","author":"NJ Cox","year":"2017","unstructured":"Cox NJ. Reaching for the next branch on the biobank tree of knowledge. Nat Genet. 2017;49:1295\u20136.","journal-title":"Nat Genet"},{"key":"1695_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"1695_CR28","doi-asserted-by":"publisher","unstructured":"Liu R, et al. Systematic pan-cancer analysis of mutation\u2013treatment interactions using large real-world clinicogenomics data. Nat Med. 2022;1\u20136. https:\/\/doi.org\/10.1038\/s41591-022-01873-5.","DOI":"10.1038\/s41591-022-01873-5"},{"key":"1695_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia EP, et al. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med. 2017;141:751\u20138.","journal-title":"Arch Pathol Lab Med"},{"key":"1695_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal Time Bias in Pharmacoepidemiology. Am J Epidemiol. 2008;167:492\u20139.","journal-title":"Am J Epidemiol"},{"key":"1695_CR31","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389:1935\u201348.","journal-title":"N Engl J Med"},{"key":"1695_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Soc Ser B (Methodological). 1995;57:289\u2013300.","journal-title":"J Royal Stat Soc Ser B (Methodological)"},{"key":"1695_CR33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD. Cox\u2019s Regression Model for Counting Processes: A Large Sample Study. Annals Stat. 1982;10:1100\u201320.","journal-title":"Annals Stat"},{"key":"1695_CR34","unstructured":"Huber PJ. University of California Press,. The behavior of maximum likelihood estimates under nonstandard conditions. in Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. 1967. Volume 1: Statistics vol. 5.1 221\u2013234."},{"key":"1695_CR35","unstructured":"Wang W. and Haoda Fu and Jun Yan. reda: Recurrent Event Data Analysis. 2025."},{"key":"1695_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1695_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1214\/aos\/1176344247","volume":"6","author":"O Aalen","year":"1978","unstructured":"Aalen O. Nonparametric Inference for a Family of Counting Processes. Annals Stat. 1978;6:701\u201326.","journal-title":"Annals Stat"},{"key":"1695_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1695_CR39","doi-asserted-by":"publisher","DOI":"10.25452\/figshare.plus.25880521.v1","author":"B DepMap","year":"2024","unstructured":"DepMap B. DepMap 24Q2 Public. Figshare+ Dataset. 2024. https:\/\/doi.org\/10.25452\/figshare.plus.25880521.v1.","journal-title":"Figshare+ Dataset"},{"key":"1695_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1:235\u201348.","journal-title":"Nat Cancer"},{"key":"1695_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"1695_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12:109\u201316.","journal-title":"Nat Chem Biol"},{"key":"1695_CR43","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow B, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 2015;5:1210\u201323.","journal-title":"Cancer Discov"},{"key":"1695_CR44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","journal-title":"Cell"},{"key":"1695_CR45","doi-asserted-by":"publisher","unstructured":"Sholl LM, Do K, Shivdasani P, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1(19):e87062. https:\/\/doi.org\/10.1172\/jci.insight.87062. Published 2016 Nov 17.","DOI":"10.1172\/jci.insight.87062"},{"key":"1695_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/ije\/dyu222","volume":"44","author":"LD Amorim","year":"2015","unstructured":"Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44:324\u201333.","journal-title":"Int J Epidemiol"},{"key":"1695_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12874-017-0462-x","volume":"18","author":"A-K Ozga","year":"2018","unstructured":"Ozga A-K, Kieser M, Rauch G. A systematic comparison of recurrent event models for application to composite endpoints. BMC Med Res Methodol. 2018;18:2.","journal-title":"BMC Med Res Methodol"},{"key":"1695_CR48","doi-asserted-by":"publisher","unstructured":"Collett D. Modelling Survival Data in Medical Research. 2023. https:\/\/doi.org\/10.1201\/9781003282525.","DOI":"10.1201\/9781003282525"},{"key":"1695_CR49","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692\u20138.","journal-title":"J Clin Oncol"},{"key":"1695_CR50","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.18632\/aging.102673","volume":"12","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging. 2020;12:4711\u201326.","journal-title":"Aging"},{"key":"1695_CR51","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.3892\/mmr.2015.3181","volume":"11","author":"W Sun","year":"2015","unstructured":"Sun W, Ma Y, Chen P, Wang D. MicroRNA-10a silencing reverses cisplatin resistance in the A549\/cisplatin human lung cancer cell line via the transforming growth factor-\u03b2\/Smad2\/STAT3\/STAT5 pathway. Mol Med Rep. 2015;11:3854\u20139.","journal-title":"Mol Med Rep"},{"key":"1695_CR52","doi-asserted-by":"publisher","first-page":"17618","DOI":"10.1038\/srep17618","volume":"5","author":"X Wang","year":"2015","unstructured":"Wang X, et al. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGF\u03b2R1\/Smad signaling pathway in NSCLC. Sci Rep. 2015;5:17618.","journal-title":"Sci Rep"},{"key":"1695_CR53","doi-asserted-by":"publisher","first-page":"e27362","DOI":"10.1371\/journal.pone.0027362","volume":"6","author":"W Geng","year":"2011","unstructured":"Geng W, et al. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS ONE. 2011;6:e27362.","journal-title":"PLoS ONE"},{"key":"1695_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44\u201356.","journal-title":"Ann Oncol"},{"key":"1695_CR55","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"1695_CR56","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12032-014-0959-7","volume":"31","author":"Y-H Jiang","year":"2014","unstructured":"Jiang Y-H, et al. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer. Med Oncol. 2014;31:959.","journal-title":"Med Oncol"},{"key":"1695_CR57","doi-asserted-by":"publisher","unstructured":"Xie P et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol S0168-8278(24)00129\u20136 (2024) https:\/\/doi.org\/10.1016\/j.jhep.2024.02.009.","DOI":"10.1016\/j.jhep.2024.02.009"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01695-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01695-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01695-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:22:45Z","timestamp":1787869365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01695-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01695-x","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dana-Farber Cancer Institute PROFILE samples were selected and sequenced from patients who were consented under institutional review board (IRB)-approved protocol 11\u2013104 and 17\u2009\u2212\u2009000 from the Dana-Farber\/Partners Cancer Care Office for the Protection of Research Subjects. Written informed consent was obtained from participants prior to inclusion in this study. Secondary analyses of previously collected data were performed with approval from the Dana-Farber IRB (DFCI IRB protocol 19\u2013033 and 19\u2013025; waiver of HIPAA authorization approved for both protocols). The research conformed to the principles of the Helsinki Declaration.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"129"}}